{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Performance Metrics
EyePoint Pharmaceuticals, Inc. has recently revised its evaluation amid changing market conditions. The company has shown impressive performance, with a 181.86% return over the past year and a remarkable 421.07% over three years, significantly outperforming the S&P 500, indicating its resilience in the pharmaceuticals sector.
EyePoint Pharmaceuticals Hits Day High with 11.22% Surge in Stock Price
EyePoint Pharmaceuticals, Inc. has seen a notable stock increase today, contrasting with the S&P 500's modest gain. Over the past week, the company has outperformed the index significantly, although it faces challenges such as declining net sales and a negative operating cash flow, alongside a high debt-equity ratio.
EyePoint Pharmaceuticals Opens with 11.81% Gain, Outperforming S&P 500's 0.69% Increase
EyePoint Pharmaceuticals, Inc. experienced a significant stock price increase today, outperforming the S&P 500. However, the company faces financial challenges, including declining net sales and negative operating cash flow. Additionally, promoter confidence has decreased, with a reduction in their stake over the last quarter.
EyePoint Pharmaceuticals Hits New 52-Week High of $14.90
EyePoint Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting a strong performance over the past year. With a market capitalization of USD 941 million, the company operates in the Pharmaceuticals & Biotechnology sector, despite facing financial challenges such as negative return on equity and a unique debt structure.
Is EyePoint Pharmaceuticals, Inc. technically bullish or bearish?
As of August 26, 2025, EyePoint Pharmaceuticals, Inc. shows a bullish technical trend supported by positive MACD and Bollinger Bands, despite a bearish monthly KST, and has significantly outperformed the S&P 500 with a year-to-date return of 84.70%.
Is EyePoint Pharmaceuticals, Inc. technically bullish or bearish?
As of May 27, 2025, EyePoint Pharmaceuticals, Inc. shows a mildly bearish trend due to conflicting signals from moving averages and Bollinger Bands, despite a recent strong monthly performance contrasting with a significant weekly decline.
Who are in the management team of EyePoint Pharmaceuticals, Inc.?
As of March 2022, the management team of EyePoint Pharmaceuticals, Inc. includes Dr. Goran Ando (Independent Chairman), Nancy Lurker (CEO), and several directors: Wendy DiCicco, Ye Liu, Ronald Eastman, Douglas Godshall, and David Guyer. They oversee the company's strategic direction and operations.
What does EyePoint Pharmaceuticals, Inc. do?
EyePoint Pharmaceuticals, Inc. develops drug delivery products for chronic eye diseases and has a market cap of $606.23 million. As of March 2025, it reported net sales of $24 million and a net loss of $45 million.
How big is EyePoint Pharmaceuticals, Inc.?
As of Jun 18, EyePoint Pharmaceuticals, Inc. has a market capitalization of 606.23 million, with net sales of 56.04 million and a net profit of -146.79 million over the last four quarters. The company's balance sheet shows shareholder's funds of 336.50 million and total assets of 418.46 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
